Nanexa and Novo Join Forces with EUR 1.165 Billion Licensing Agreement

Introduction

On September 25, 2026, Nanexa AB, a Swedish company specializing in drug delivery solutions, announced a monumental EUR 1.165 billion licensing and collaboration agreement with Novo Nordisk. This partnership marks a significant advancement in the development of long-acting injectable drugs, specifically targeting therapeutic applications for obesity and type 2 diabetes among other cardiometabolic conditions.

Understanding the Collaboration

At the heart of this agreement lies Nanexa's proprietary PharmaShell® technology. This advanced platform employs atomic layer deposition (ALD) techniques to create long-acting injectable formulations designed to enhance drug delivery efficacy. Under this collaboration, Novo Nordisk has secured a global exclusive license to utilize the PharmaShell® technology across multiple development programs aimed at addressing chronic diseases that afflict millions worldwide.

The agreement allows for the development of products with varied administration frequencies, targeting monthly and quarterly schedules, which is expected to improve patient compliance and therapeutic outcomes. Novo will spearhead the global development and commercialization of these innovative therapies while Nanexa stands to receive substantial financial compensation, including an upfront payment of EUR 615 million alongside potential milestone payments that may total up to EUR 1.165 billion.

The Significance of PharmaShell® Technology

PharmaShell® represents a cutting-edge approach to drug delivery through its ultra-thin inorganic coating that sustains the release of active pharmaceutical ingredients. This technique not only aims to minimize dosing frequency but also seeks to enhance the overall treatment experience for patients suffering from chronic metabolic and cardiovascular diseases. By optimizing the delivery mechanism, the partnership intends to meet the growing demand for more effective and patient-friendly therapies in the pharmaceutical landscape.

According to David Westberg, CEO of Nanexa, this collaboration validates the versatility of the PharmaShell® platform and sets the stage for expanding its applications into more therapeutic areas. Riding on the momentum of their previous agreement with Moderna in 2025, this new venture with Novo strengthens the foundation for Nanexa's future projects and initiatives aimed at clinical proof of concept.

Future Perspectives

The financial framework established through this agreement empowers Nanexa to explore additional applications of the PharmaShell® technology beyond the immediate scope of obesity and type 2 diabetes. Göran Ando, Chairman of Nanexa, expressed optimism for the company’s future, noting that the collaboration places them in a position of considerable financial strength. This will enable Nanexa to develop new projects independently before engaging in future partnerships, thereby maximizing the potential value derived from their technology.

Moreover, by focusing on creating an effective partnership with Novo, Nanexa aims to enhance its capabilities, thereby positioning itself as a key player in the pharmaceutical industry. The collaborative efforts are expected to yield significant advancements in the treatment of chronic conditions that have significant public health implications.

Conclusion

The alliance between Nanexa and Novo Nordisk is a testament to the evolving landscape of drug delivery technologies and the collaborative efforts necessary to tackle pressing health issues such as obesity and diabetes. As these companies embark on this robust partnership, the benefits could translate into improved therapeutic options for patients globally. The anticipated innovations from their combined expertise in drug formulation and delivery are poised to redefine treatment modalities in the coming years, rendering them pivotal players in the healthcare sector.